NVO NYSE Week ended 31 Jul 2026

Weekly Investor Report

Novo Nordisk A/S · Healthcare · Drug Manufacturers - General

Open interactive chart View report data
Latest close 47.08 USD
-3.5% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is 3.8% above the Trend Line and sits at 45.4% of its 52-week range. The latest completed week returned -3.5%, after a -6.6% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is inexpensive relative to peers. Options positioning is bullish with 41/100 conviction, while the latest news-sentiment score is 53/100. Near-term considerations: earnings are due in 3d.

Setup score 34 out of 100
Latest Close 47.08 USD 31 Jul 2026
1W Return -3.5% latest completed week
4W Return -6.6% short-term follow-through
12W Return 2.2% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 1.0x vs 13-week average
What is working
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • The share remains more than 20% below its 52-week high.
  • Latest weekly return ranks in the weaker part of its sector group.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -3.5% Latest completed week; four-week move -6.6%. Indicator stack 0/64 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 41/100 conviction; expected move 6.8%. News sentiment 53/100 63 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is 3.8% above the Trend Line and sits at 45.4% of its 52-week range. The latest completed week returned -3.5%, after a -6.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.4612-week average 0.26

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.46Current proprietary activity-pressure read.
Buy signals3Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -6.6% over four weeks, 2.2% over 12 weeks, and 2.2% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-3.5%
4W-6.6%
12W2.2%
26W-18.0%
52W2.2%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.78Latest activity-pressure read.
Pressure change-2.3%Four-week change in activity pressure.
Leadership-9.49Latest relative-leadership reading.
RS change-56.5%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is inexpensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 100% Model confidence 96%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength90/100Blend of value, momentum, and quality. Underlying universe rank 11; rank 1 is best.
Value98/100Relative valuation strength. Underlying universe rank 3; rank 1 is best.
Quality95/100Profitability and accounting quality. Underlying universe rank 6; rank 1 is best.
Momentum12/100Medium-term price momentum. Underlying universe rank 89; rank 1 is best.
Growth78/100Revenue and earnings growth. Underlying universe rank 23; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
1.8x
Price divided by trailing earnings.
Price / sales
0.7x
Market value relative to trailing revenue.
EV / EBITDA
1.8x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
60.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
81.8%
Gross profit retained from each unit of revenue.
Operating margin
50.1%
Operating profit retained from revenue.
Free-cash-flow margin
62.9%
Free cash flow generated from revenue.
Return on invested capital
39.2%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
8.1%
Latest one-year revenue growth.
EPS growth
16.6%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
9.6%
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
3.8%
Cash dividends relative to market value.
Buyback yield
1.1%
Net share repurchases relative to market value.
Shareholder yield
4.9%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

NVO shows bullish options pressure with a 41/100 conviction score, put-call volume ratio of 0.53, expected move of 6.8%, and Sharemaestro trend signal inactive.

Conviction41/100
Expected move6.8%
Put/call volume0.53
Pressure35
Speculation42
Volatility70
Trend agreement39
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment53/100

Weighted news tone is neutral across 63 relevant articles.

19 positive · 33 neutral · 11 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move6.8%Nearest-chain priced movement where available.
52-week drawdown-24.1%Distance below the 52-week high.
13-week volatility4.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+11.3%Week of 26 Jun.
Worst week-21.0%Week of 27 Feb.
Latest week-3.5%Week of 31 Jul.

Shape of recent returns

Strong gains7
Modest gains7
Flat weeks0
Modest losses8
Sharp losses4
Recent vol4.4%13-week weekly-return volatility.
Base vol6.6%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew5.5% / -4.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape33/100

Trend, activity pressure, participation, and risk combine to a 33/100 tape read.

 Indicator analysis36/100

Latest 12-week confirmation: trend 0/12, activity pressure 11/12, relative leadership 0/12.

Activity pressure 0.46; No reversal markers Factors75/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Cornerstone Growth rank 92; Buyback Yield rank 30 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Options53/100

NVO shows bullish options pressure with a 41/100 conviction score, put-call volume ratio of 0.53, expected move of 6.8%, and Sharemaestro trend signal inactive.

Bullish · Call-side pressure · Expected move 6.8% Sentiment53/100

Weighted news tone is neutral across 63 relevant articles.

Novo Nordisk (NVO) Trial Setback Hits Sentiment, Is The Stock Still Cheap? Insiders50/100

No recent insider transaction evidence is stored.

 Earnings3d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.

 Research flow2 items

0 recent research articles and 2 Market Watch posts are available.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202647.08 USD-3.5%45.35 USD80.42 USD0.78-9.4962.4MOff
24 Jul 202648.77 USD-3.1%45.47 USD80.59 USD0.83-5.5340.4MOff
17 Jul 202650.32 USD1.7%45.53 USD80.74 USD0.92-4.2343.7MOff
10 Jul 202649.48 USD-1.9%45.40 USD80.91 USD0.78-8.0645.5MOff
3 Jul 202650.43 USD4.9%45.37 USD81.07 USD0.80-6.0741.2MOff
26 Jun 202648.07 USD11.3%45.23 USD81.21 USD0.75-9.4782.5MOff
19 Jun 202643.19 USD-1.6%45.22 USD81.39 USD0.63-21.4636.2MOff
12 Jun 202643.88 USD2.1%45.31 USD81.58 USD0.66-20.7579.5MOff
5 Jun 202642.96 USD-5.7%45.41 USD81.78 USD0.59-23.3668.8MOff
29 May 202645.58 USD1.4%45.45 USD81.97 USD0.47-21.9546.3MOff
22 May 202644.96 USD0.5%45.52 USD82.15 USD0.26-22.9857.6MOff
15 May 202644.74 USD-2.9%45.73 USD82.34 USD-0.03-23.6771.8MOff
8 May 202646.07 USD5.0%45.99 USD82.56 USD-0.35-22.0799.8MOff
1 May 202643.88 USD6.6%46.29 USD82.78 USD-0.63-24.93103.6MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.